{
    "clinical_study": {
        "@rank": "121176", 
        "acronym": "DKD-EXT", 
        "arm_group": [
            {
                "arm_group_label": "Exercise", 
                "arm_group_type": "Experimental", 
                "description": "blended supervised-hombased exercise training 3-4 times/week for 12 weeks"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "control group asked to continue usual activities"
            }
        ], 
        "brief_summary": {
            "textblock": "The general objective is to investigate the effect of a 12 week walking exercise program on\n      vascular endothelial function, arterial stiffness/compliance, and vascular health biomarkers\n      in men and women with pre-dialysis type 2 diabetic kidney disease (DKD)."
        }, 
        "brief_title": "Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Focus Type 2 Diabetes Related Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Diabetic Nephropathies", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 An individual must be >18 years of age\n\n        Have diagnosed type 2 diabetic mellitus by one of the following criteria:\n\n        o Treated with diet, diet plus oral hypoglycemic agents (for at least one year), or\n        insulin preceded by treatment with oral agents (for at least one year).\n\n        If treated with insulin, the onset of diabetes must have occurred after age of 40 and the\n        body mass index must be >25kg/m2 at the time of diagnosis.\n\n        Diagnosed kidney attributed to diabetes by one of  the following criteria:3\n\n          -  Macroalbuminuria (ACR >300mg/g, or)\n\n          -  Microalbuminuria (ACR between 30-300 mg/g) or in the presence of diabetic retinopathy\n             (although is recognized that about 1/3 of type 2 diabetics do not have retinopathy by\n             fundoscopic exam).\n\n          -  An elevated ACR should have been confirmed in the absence of urinary tract infections\n             with 2 additional first-void specimens collected over 3-6 months.\n\n          -  At least 2 of 3 samples should fall within the range of micro or macroalbuminuria.\n\n               -  An estimated Glomerular filtration rate (GFR) of between 90 ml/min and 30 ml/min\n                  measured by  (GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if\n                  female) x (1.210 if African-American) (conventional units).\n\n               -  Individuals must be able to provide informed consent\n\n               -  Perform walking exercise testing on a treadmill\n\n               -  Be able to participate in a 12-week supervised exercise program.\n\n        Exclusion Criteria:\n\n          -  \u2022 Patients are currently exercising\n\n               -  Requiring dialysis\n\n               -  Have an Hematocrit <30%\n\n               -  Uncontrolled hypertension (>200/100mmHg)\n\n               -  Peripheral vascular disease.\n\n               -  An inability to understand English or give consent. Other exclusion criteria\n                  are: any contraindications to exercise testing or training as indicated by the\n                  American College of Sports Medicine guidelines such as: Unstable coronary heart\n                  disease and symptomatic heart failure, exercise capacity limited by health\n                  problems such as angina, severe arthritis, or extreme dyspnea on exertion,\n                  progressive neuromuscular disease, pulmonary disease., or having undergone a\n                  coronary revascularization within the past 6 months prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "122", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112071", 
            "org_study_id": "0905M66282", 
            "secondary_id": [
                "K23DK082638-04", 
                "22275"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Exercise", 
            "description": "Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.", 
            "intervention_name": "Exercise", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Exercise", 
            "Diabetic kidney disease", 
            "vascular function", 
            "physical function"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.", 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Ulf G Bronas, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Endothelium-mediated change in in vascular tone", 
            "measure": "endothelial function measured by brachial artery flow mediated vasodilation", 
            "safety_issue": "No", 
            "time_frame": "at week 0 and at week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112071"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "investigator_full_name": "Ulf G. Bronas", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "arterial stiffness measured by pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "description": "C-reactive protein, isoprostane F2, Asymmetric dimethylarginine", 
                "measure": "Circulating markers of vascular health", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "description": "Peak oxygen consumption", 
                "measure": "aerobic capacity", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "measure": "blood pressure", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }, 
            {
                "description": "assessed in 30 participants measured in milligram per gram creatinine", 
                "measure": "24-hour albuminuria", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and at week 12"
            }
        ], 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}